Related Experiment Videos
[Colorectal carcinoma in elderly patients]
1Medizinische Universitätsklinik, Ruhr-Universität Bochum.
Praxis
|January 19, 2006
Summary
Elderly patients over 70 with colorectal cancer can receive standard chemotherapy with equal tumor response and manageable toxicity. Treatment decisions should consider overall patient health and capacity.
Area of Science:
- Oncology
- Geriatric Medicine
- Clinical Pharmacology
Context:
- Colorectal cancer incidence rises in patients over 70 due to increased life expectancy.
- Elderly patients are often underrepresented in clinical trials for colorectal cancer chemotherapy.
- Lack of specific data for this demographic leads to uncertainty in treatment decisions.
Purpose:
- To evaluate the efficacy and toxicity of standard chemotherapy regimens in elderly patients (over 70) with colorectal cancer.
- To provide evidence-based recommendations for chemotherapy use in older adults with colorectal cancer.
Summary:
- Chemotherapy demonstrates equal tumor response in patients over 70 compared to younger cohorts for standard agents like 5-FU, folinic acid, capecitabine, irinotecan, and oxaliplatin.
- While some 5-FU-based combinations show increased toxicity in older adults, other agents do not exhibit age-specific differences.
- State-of-the-art chemotherapy should be offered to elderly patients in both adjuvant and palliative settings.
Impact:
- Supports the use of standard chemotherapy in elderly colorectal cancer patients, improving treatment access.
- Highlights the need for individualized treatment decisions considering patient performance and organ function.
- Encourages further research and inclusion of elderly patients in clinical trials.